Phase 1b Trial to Test TAR-200, Opdivo Combo as Treatment for Muscle Invasive Bladder Cancer
News
A new Phase 1b clinical trial will evaluate if combining TAR-200 (GemRIS), a chemotherapy-releasing agent, and Opdivo (nivolumab) is a safe, well tolerated, and efficacious approach for the treatment of muscle ... Read more